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Relative roles of elastase and reactive oxygen species in the degradation
of human glomerular basement membrane by Intact human neutrophils.
Glomerular basement membrane (GBM) damage and proteinuria occur-
ring during the early phase of acute glomerulonephritis are often
neutrophil (PMN) dependent. The present study sought to identify the
potential roles of PMN derived elastase and reactive oxygen species
(ROS) in the pathogenesis of glomerular basement damage in an
homologous in vitro model of anti-GBM nephritis using intact PMN.
Human PMN (5 x 106), incubated with human GBM (0.5 mg) pre-
treated with human anti.GBM IgG, degraded 10.3 1.1% of the GBM
type IV collagen in six hours (8 igfhr), and underwent a two-hour
respiratory burst. The same number of sonically disrupted PMN
solubulized 22.4 5.4% of GBM under the same incubation conditions.
The inclusion of the elastase inhibitors alpha 1 proteinase inhibitor
(alPi), and a smaller highly-specific synthetic compound (L658 758),
reduced degradation by PMN homogenates by 84.8% and 85.7%,
respectively, whereas they were only able to inhibit intact PMN
mediated degradation by a maximum of 49.2% and 50.9%, respectively.
The inclusion of EDTA (10 mM), an inhibitor of metalloproteinases,
reduced GBM degradation by APMA activated and disrupted PMN by
only 7.5%. Incubation of PMN with diphenylene iodonium (DPI)
abolished PMN reactive oxygen species generation by >95% but
preserved elastase release. This compound did not directly affect GBM
degradation. It did, however, abolish the inhibitory effect of ROS on
alPi activity and thus indirectly reduced GBM damage by up to 20%.
A number of human and experimental glomerulonephritides
are characterized by the infiltration of glomeruli with PMN
[l-.4]. Animal models of anti-basement membrane nephritis
have highlighted the role of these cells in the pathogenesis of the
heterologous phase of proteinuria [5—7]. The development of
proteinuria is thought to reflect glomerular basement membrane
(GBM) damage by PMN recruited after antibody binding. This
hypothesis is supported by the identification of increased uri-
nary excretion of basement membrane fragments and PMN
proteinases by patients with rapidly progressive glomerulone-
phritis [8]. The destruction of GBM, and its individual compo-
nents, by PMN has been attributed to their ability to release
both reactive oxygen species (ROS) [6—9] and neutral protein-
ases [5, 10—13] during the acute inflammatory response. The
relative importance of both mediator systems as direct damag-
ing agents and the role of anti-proteinases is still unresolved
[14—17]. In addition the hypothesis that oxygen radical-medi-
ated inactivation of alPi results in significantly enhanced pro-
teolytic tissue damage remains unproved [14, 16, 18]. Previous
studies have used either heterologous systems [19, 20] or
non-physiological soluble stimuli such as phorbol myristate
acetate (PMA) [14—16] to investigate the mechanisms of PMN
mediated matrix damage. In the present study the role of
neutrophils in the pathogenesis of GBM degradation, was
studied in an homologous human, intact cell, in vitro model of
anti-GBM nephritis to mirror the in vivo pattern of anti-GBM
nephritis as closely as possible.
Methods
PMN preparation
Neutrophils were prepared using a modified Ficoll-Paque
(Pharmacia LKB Biotechnology, Uppsala, Sweden) density
gradient centrifugation technique. Briefly 5 ml aliquots of whole
blood were anticoagulated with 0.5 ml citrate solution (170 mt
tn-sodium citrate, 75 m citric acid, pH 5.6), layered onto 1 ml
dextran 70 solution (6% Dextran 70 in 0.9% NaCI, Baxter, UK)
and incubated at 37°C for 45 minutes. The buffy coat was then
washed x4 in cold phosphate-buffered saline pH 7.3 (PBS) with
a low speed centrifugation (300 x g) in between each wash. The
leukocyte pellet was then carefully resuspended in cold PBS,
layered onto a Ficoll-Paque density gradient and centrifuged at
400 x g for 35 minutes. After four more washes the remaining
erythrocytes in the pellet were lysed in cold 0.2% NaCl. The
neutrophils were then washed x3 in PBS. Preparations com-
prised >95% neutrophils (phase contrast microscopy) and were
>95% viable as judged by the exclusion of Trypan blue dye.
Sonicated PMN were prepared from each fresh batch by
using a stainless steel ultrasonic disrupter (MSE Scientific, UK)
for S x 45 second bursts at 10 m peak to peak intensity with
one minute cooling on ice in between. In all experiments
neutrophils from six different donors were studied.
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Glomerular basement membrane preparation
Human glomerular basement membrane (GBM) was pre-
pared at 4°C by a method based on that of Westberg and
Michael [21]. Sliced cadaver renal cortex was forced through a
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series of decreasing size stainless steel sieves (425, 180, 125,
and 90 sm) and washed through with copious amounts of cold
PBS. Glomeruli (>95%) were isolated on the 125 pm mesh with
tubules and capsular debris on the 90 m sieve. Glomeruli were
washed x 4 in cold PBS to remove proteinacious debris and
then intrinsic glomerular cells were disrupted in 0.1% Triton
X-100 at 37°C for 30 minutes. The resulting homogenate was
centrifuged at 200 x g for 15 minutes, washed x4 with PBS, and
centrifuged another four times at 3000 x g (5 mm) with washes
in distilled water, after which the pellet of GBM was lyophi-
lized. A mean of 30 mg GBM/100 g cortex (range 5 to 80 mg)
was obtained and individual preparations were pooled. Micro-
scopic analysis of the prepared GBM revealed typical appear-
ances as previously published [21] and an absence of either
cellular or interstitial debris. GBM was free of DNA and judged
endotoxin free using a commercially available limulus amoebo-
cyte lysate assay (E-Toxate, Sigma, Poole, UK) [221. There was
no evidence of intrinsic proteinase activity within the GBM
preparations.
Anti-GBM and normal IgG preparation
Anti-GBM IgG was prepared by Sepharose protein-A affinity
chromatography of plasma obtained during the first and second
plasmapharesis of a patient with biopsy and serologically
proven anti-GBM disease. IgG eluates were titrated to pH 7.4,
dialyzed against distilled water, and lyophilized. Normal con-
trol human IgG was prepared in an identical manner from
pooled normal human serum. Preparations were pure IgG as
assessed by SDS-PAGE with silver stain, and were judged
endotoxin-free by the limulus amoebocyte lysate assay. IgG
immunoreactivity with GBM was assessed by ELISA using a
collagenase digest of GBM as the solid phase. Binding of the
IgG preparations to GBM was assessed using radiolabeled IgG.
Normal and anti-GBM IgG were labeled with 125j using lodo-
beads (Pierce, Rockford, Illinois, USA) according to the man-
ufacturer's instructions. Approximately I g of anti-GBM IgG
bound to each mg of GBM after 16 hours incubation at 37°C and
there was no detectable bound normal IgG.
Inhibitors
Human alPi was obtained from Sigma and was dissolved in
PBS to the required concentration. L658 758, a highly specific
inhibitor of human neutrophil elastase [23] (A gift of Dr. P.
Davies Merck Sharp and Dohme, Rahway, New Jersey, USA),
was supplied as a white powder and dissolved in PBS to the
required concentration. Analar grade ethylene diamine tetra
acetic acid (EDTA) was purchased from BDH chemicals.
Diphenylene iodonium (DPI; a gift from Prof. 0. Jones, Uni-
versity of Bristol, UK), a potent inhibitor of the PMN NADPH
oxidase system which completely abolishes their respiratory
burst [24], was prepared as a stock solution (10 m in dimethyl
sulphoxide) and diluted to the required concentration in PBS.
In preliminary experiments the PMN respiratory burst activ-
ity was unaffected by proteinase inhibitors and the degranula-
tion of PMN was unaltered by DPI. No inhibitor used with
intact PMN reduced their viability as assessed by the release of
LDH or their ability to exclude Trypan blue dye. In addition
none of the inhibitors were shown to interfere with the assays
used in the study.
In vitro model of anti-GBM nephritis
Experiments were performed using a human in vitro model of
anti-GBM nephritis. GBM (10 mg) was pre-treated by incubat-
ing with pure IgG isolated from either anti-GBM positive
plasma or normal serum (1 mg IgG/mg GBM) in Krebs-Ringer
phosphate glucose buffer, pH 7.3 (KRPG: Na2HPO4 10 mM,
NaH2PO4 2HO 3 mrvi, NaCl 120 mM, KC1 4.8 mri, CaCl2 0.54
mM, MgSO . 7H20 1.2 mi, b D-glucose 11 mM), for 16 hours
at 37°C. Following this the GBM was washed three times in
KRPG. Normal IgG pre-treated GBM is designated control
GBM and GBM pre-treated with anti-GBM IgG is abbreviated
GBMIgG*. PMN (5 X 106) were incubated with the control
GBM or GBMIgG* (0.5 mg) for varying periods of time in 1 ml
KRPG at 37°C. PMN incubated without GBM served as nega-
tive controls, and phorbol myristate acetate (PMA 1 sM) was
used as an independent, positive control, neutrophil stimulus.
Experiments were carried out in a non-agitated system in which
neutrophils settled onto the GBM during incubation.
Measurement of GBM collagen IV degradation
The extent of GBM degradation was measured by the release
of soluble hydroxyproline containing peptides into the incuba-
tion supernatants by a modified chloramine T method [25].
After incubation, the supernatant and pellet were separated by
centrifugation for five mm at 4000 x g, made up to a known
volume with 0.9% NaC1 and mixed with an equal volume of 12
M HC1. Samples were sealed in glass ampoules and heated for
16 hours at 105°C. The resulting hydrolyzed samples were
neutralized alternately with increasingly dilutions of NaOH and
HCI. Finally, 100 l of assay buffer (citric acid 0.24 M, glacial
acetic acid 6 ml, sodium acetate 0.87 M, sodium hydroxide 0.85
M, pH 6.0) per ml of sample were added. Final volumes were
adjusted with 0.9% NaCI and 1 ml removed for hydroxyproline
determination. Aliquots were mixed with an equal volume of
chioramine T solution (chloramine T 0.35 g, distilled H20 20 ml,
2-methoxyethanol 30 ml, assay buffer 50 ml) at room tempera-
ture for five minutes. One ml of an equal mixture of perchloric
acid (27 ml of 70% solution in 73 ml distilled H20) and
dimethylaminobenzaldehyde (5 g in 100 ml propan-2-ol) was
added, mixed thoroughly and heated at 65°C for a further 20
minutes. Hydroxyproline was detected by the development of a
pink color measured at 560 nm on a Cecil CE 292 spectropho-
tometer (Cecil Instruments, Cambridge, UK). Concentrations
were determined from a standard curve using pure L-hy-
droxyproline 0 to 5 g/ml. Results are expressed as the percent
total hydroxyproline released by dividing the total supernatant
hydroxyproline by the sum of the pellet plus supernatant values
for each incubation.
Measurement of PMN activation
Respiratory burst activity. PMN respiratory burst activity
was determined over a 120 minute incubation at 37°C by luminol
(50 /.LM) enhanced chemilurninescence [26] using a Berthold LB
950 spectrophotometer (Berthold Instruments, St Albans, UK).
PMA (1 M) was used as an independent positive control.
Results are expressed as mean counts per minute, or integrated
counts over 120 minutes (± SEM) less the values for cells
incubated in the absence of GBM.
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Fig. 1. Effects of GBMIgG* (•) and control GBM (0) stimulation on
the degradation of GBM over a six hour incubation period. #P < 0.05
as compared to control GBM values at each time point.
PMN degranulation. Degranulation of PMN was measured
by published methods for the detection of myeloperoxidase,
vitamin B12 binding protein and gelatinase [27].PMA was used
as a positive control for degranulation experiments.
PMN viability
Neutrophil viability during and after incubations was deter-
mined by the release of lactate dehydrogenase (LDH). The cells
were pelleted by low speed centnfugation (150 X g) and the
supernatants assessed for LDH activity in a microtiter plate
reader (MR5000/340, Dynatech Laboratories mc, Billingshurst,
UK) as described below. Briefly, 150 tI of supernatant were
incubated, in triplicate, in a microtiter plate with 20 d, 4.0 mrvi
b-nicotinamide adenine dinucleotide (NADH reduced form,
Sigma, Poole, UK) and 10 xl, 7.2 m sodium pyruvate for 12
minutes at 25°C. At one minute intervals the optical density of
the mixture was measured at 340 nm and the resulting negative
optical density gradient calculated. LDH release was calculated
as a percentage of the gradient obtained from sonicated PMN
prepared on the same day with the same cell preparation.
Cell-free control systems
In addition to the intact cell model, cell free systems were
used to assess the efficacy of the elastase inhibitors and the
relative contribution of human PMN elastase (HNE) and met-
alloproteinases to GBM degradation. Briefly either control
GBM (0.5 mg) or GBMIgG* (both gave identical results) was
incubated for six hours with either sonicated PMN (5 x 106 in
KRPG), or pure HNE (10 p.g; a gift from Dr. P. Davies, Merck
Sharp and Dohme, Rahway, New Jersey, USA), in the pres-
ence of increasing concentrations of two elastase inhibitors,
L658 758, a specific low molecular weight compound [23] and
alPi. In addition the metallo-ion chelator EDTA was used to
assess the PMN content of neutral metalloproteinases both with
and without activation of any latent metalloproteinases by
APMA (10 mM). Published data indicate that PMN contain a
total of - 2 jxg elastase per million cells [28]. Ten micrograms of
elastase were used in the cell free model to reflect the total
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Fig. 2. Inhibition of GBM degradation by human neutrophil elastase(10 jxg) by 2 elastase inhibitors at various concentrations. Symbols are:
(0) alpha I Pi; (0) L 658, 758.
available enzyme from the 5 x 106 PMN used in the intact cell
system. Degradation of 0.5 mg of GBM in 1 ml of KRPG was
assessed by the release of hydroxyproline rich peptides. Inhib-
itor efficacy was calculated by comparing hydroxyproline re-
lease obtained with and without inhibitor.
Statistical analysis
Experiments were carried out in triplicate using PMN from
six different donors. The mean data (N 6) were compared
using the paired Student's t-test. P values less than 0.05 were
considered to be significant.
Results
GBM degradation
Degradation of GBM was determined after incubation peri-
ods of up to six hours, since after this time LDH release from
PMN rose to supernormal levels (data not shown), indicating
loss of cell viability with possible uncontrolled release of
intracellular contents.
The mean hydroxyproline release following the interaction of
5 x 106 PMN with GBMIgG* was 10.3 1.1% whereas control
GBM only caused 2.3 0.9% release (N = 6; P < 0.05).
Degradation of GBMIgG* was dependent on PMN number
reaching a maximal degradation of 11.0% using iO PMN.
Stimulation of PMN with PMA induced a mean of 24.6%
degradation after six hours incubation. Interestingly, although
PMA stimulated PMN produced detectable granule markers in
the supernatant, when PMN were stimulated by GBMIgG*,
basement membrane degradation occurred in the absence of
detectable granule markers. PMN incubated in the presence of
GBMIgG* produced significantly more degradation at each
time point as compared to control GBM (Fig. 1).
In the cell free systems GBM degradation by pure PMN
elastase was 32.4% after six hours. This was inhibitable by both
L658 758 and alPi in a dose-dependent fashion, and both
inhibitors were approximately equipotent on a molar basis (Fig.
2). Using sonically disrupted PMN, degradation was 22.6%
after six hours, and both inhibitors achieved >84% inhibition
(Fig. 3). The metallo-ion chelator EDTA at 10 m or greater
concentrations only inhibited degradation of GBM by PMN
Fig. 3. Effects of sonically disrupted 5 x 106 PMN on the degradation
of GBM in the absence and presence of protease inhibitors alPi (200
nM), L 658758 (200 nM) and EDTA (10 mM). Latent metalloproteinases
were also activated using APMA (10 mM) and co-incubated with EDTA.
Inhibitor concentration, flM
Fig. 4. Effects of increasing concentrations of elastase inhibitors on
the degradation of GBM by 5 x 106 intact PMN stimulated by GBM-
lgG* (0.5 mg). Symbols are: (0) alpha I Pi; (0) L 658758.
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FIg. 5. PMN luminol enhanced chemiluminescence versus time from 5
x 106 PMN stimulated by GBMIgG* (I) and control GBM (0)
expressed as counts per minute (c.p.m. x 10—6).
Table 1. Comparison of three different stimuli on the extent of PMN-
derived luminol-enhanced chemiluminescence and the effects of
dipenylene iodonium (DPI) pre-treatment of PMN
Neutrophil stimulus(N = 6)
Chemiluminescence
without DPI
Chemiluminescence
with DPI (10 jsM)
GBM (0.5 mg) 3.12 0.57 0.24 0.09
GBMIgG* (0.5 mg) 35.94 7.15 2.36 0.34
PMA (I sM) 527.56 100.69 9.86 2.55
Chemiluminescence is expressed as integrated counts x l0_6 over a
120-minute incubation period.
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peak at a mean time of 48 minutes and declining to baseline
10 100 1000 10000 levels after 120 minutes. Both peak and integrated chemilumi-
nescence were substantially greater from PMN incubated with
GBMIgG* (Fig. 5). However, integrated CL over 120 minutes
was substantially lower with GBMIgG* as the PMN stimulus
than with PMA (Table 1). Control incubations of neutrophils
with both anti-GBM and normal IgG in the absence of GBM did
not induce CL.
In the presence of DPI (10 SM), CL was reduced by over 95%
(Table 1) without affecting either cell viability or degranulation.
Normal PMN and those incubated with DPI (10 FM), to abolish
ROS production, showed no difference in their ability to de-
grade the basement membrane collagen. After six hours the
mean degradation of GBMIgG* was 9.6 1.1% in the presence
of DPI and 9.9 0.9% without it (P = NS). In addition, the
degradation of GBM by PMA (1 M) stimulated PMN, which
generate 15-fold quantities of ROS when compared to GBM-
IgG* stimulus (Table 1), was also unaffected by DPI.
sonicates by up to 6.5% without APMA activation and by 7.5%
with APMA (Fig. 3), and did not enhance the effect of HNE
inhibitors. This indicates a relatively low contribution from
PMN metalloproteinases in GBM degradation.
When the HNE inhibitors were used with intact PMN stim-
ulated by GBMIgG* the maximal effects of both were mark-
edly reduced. A maximum of only 50% inhibition of GBM
degradation could be achieved despite increasing the concen-
tration of both inhibitors to well above that needed to inhibit
either all calculated available elastase or >84% PMN granule
activity (Fig. 4).
Reactive oxygen species generation
Incubation of PMN with control GBM and GBMIgG* pro-
duced a prolonged very low grade respiratory burst, reaching a
Interactions between ROS and elastase inhibitors
The effects of PMN derived ROS on the function of both
elastase inhibitors were studied using normal and DPI treated
PMN. The capacity of each inhibitor to reduce GBM degrada-
tion by DPI treated PMN was compared to their ability to do the
same with normal PMN. The change in elastase inhibitory
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capacity of each inhibitor was calculated by the following
formula:
100 x [(% inhibition with normal PMN)
— (% inhibition with DPI treated PMN)/
(% inhibition with DPI treated PMN)]
While DPI treated PMN were able to degranulate and release
HNE normally they were unable to generate ROS. Thus, any
differences between the effects of DPI treated and normal PMN
on the elastase inhibitory capacity of alPi are due to the
presence of ROS from the normal PMN. The elastase inhibitory
capacity of alPi was significantly reduced by up to 22.7% when
it was present in low concentration, the effect becoming less
pronounced as alPi concentration increased (Fig. 6). In con-
trast L 658 758 was not significantly affected by ROS (Fig. 6).
Discussion
The present study used a homologous in vitro human model
of anti-GBM nephritis which allowed analysis of the pathophys-
iological processes which might lead to in vivo PMN mediated
GBM degradation. Damage to the GBM is widely perceived to
be the cause of proteinuria during acute glomenilonephritis
(GN) [161. The binding of antibody to GBM is followed by
intraglornerular accumulation of PMN [5—7] upon which the
early phase of proteinuria is dependent. In the present investi-
gation, solubulization of the principal component of GBM, type
IV collagen, was predominantly PMN elastase mediated. Spe-
cific elastase inhibitors of differing size significantly ameliorated
GBM degradation, though incompletely. Reactive oxygen spe-
cies did not directly cause GBM degradation but they did
reduce the elastase inhibitory capacity of alPi when it was
present in low concentrations.
Neutrophil derived ROS [9, 29, 30] and neutral proteinases
such as elastase [28, 31] are both thought to be important in the
pathogenesis of tissue damage. Previous work has shown that
human PMN, when appropriately stimulated have the potential
to degrade GBM [10, 19, 20]. Data from these models show a
penetrate the cell-substrate milieu and prevent degradation of
substrate. In the present study, despite using a 0.4 kD elastase
inhibitor (L658 758), no difference in activity was seen com-
pared to the larger alPi. Although effective penetration of the
cell-substrate may have occurred there are several reasons why
these inhibitors may have been ineffective. Despite using well
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Fig. 6. Changes in the elastase inhibitory capacity of alPi (•) and L
658758 () at various concentrations in the presence of normal PMN
as compared to PMN pre-treated with DPI. # <0.05 as compared to
e!astase inhibitory capacity in the presence of normal PMN.
comparable degree of GBM damage to that in our system.
However, these models used heterologous anti-whole GBM
antibodies [10], or heterologous antibody sandwiches/immune
complexes [19, 20]. In addition, others have used the non-
specific soluble PMN stimulus PMA, whose physiological rel-
evance is unknown. GBM degradation using this stimulus is
significantly greater over the same time course both in our
model and others. In the present system we used a homologous
anti-GBM IgG which recognizes the Goodpasture epitope
within the NC-i domain of type IV collagen to provide a close
analogy to the in vivo pattern of anti-GBM disease.
The ability of functional neutrophils to induce GBM degra-
dation was only partially ameliorated by elastase inhibitors of
12.5 25 50 100 200 400 two markedly differing sizes. L 658 758 is a 0.4 kD synthetic
specific PMN elastase inhibitor, with no activity against other
proteinases, from a class of compounds shown to prevent
elastase induced lung damage in animals [23]. Alpha 1 Pi, a 51
kD glycoprotein, is the most important natural inhibitor of
elastase but also has less potent inhibitory effects on other
proteinases [32]. GBM degradation by PMN sonicates and pure
HNE were inhibited equally by both L 658 758 and alPi by
more than 84% and 94%, respectively. Furthermore, combina-
tions of both inhibitors did not enhance this. Under the same
conditions the addition of EDTA, which inhibits metalloprotei-
nases in vitro, only reduced degradation by sonicated PMN by
6.5% indicating the relatively low activity of metalloproteinases
in our system. Further treatment of the PMN sonicates with the
organomercurial compound APMA, which has been shown to
activate latent metalloproteinases in vitro, only marginally
influenced GBM degradation and increased EDTA inhibitable
degradation from 6.5% to 7.5%. Interestingly, although PMN
metalloproteinases are stored in a latent form, previously
published data have shown that following sonication almost all
released metalloproteinase is in an active form [27]. These
results from the cell free system indicate that up to 84% of GBM
degrading activity within PMN may be HNE mediated. The
small deficit in GBM degradation not specifically accounted for
by either metalloproteinases or HNE may be due to the effects
of other relatively minor PMN proteinases such as cathepsin G.
In the intact cell model two effects were seen. Firstly, the
degradation of GBM over a six hour period was approximately
50% of maximal achieved by sonicated PMN. The extent of
degradation detected with intact PMN was similar to that seen
in other models which have used a heterologous antibody
stimulus [10], but much lower than that seen with PMA.
Secondly, the maximal inhibition achieved by both elastase
inhibitors was only 50%. This significant decrease in inhibitor
efficacy cannot be solely explained by the actions of other PMN
enzymes since, as detailed above, sonicated PMN mediated
degradation was —84% HNE mediated, with only minor possi-
ble contributions from either metalloproteinases or cathepsin
G. Previous in vitro studies have suggested that smaller inhib-
itors such as secretory leukoprotease inhibitor (4 kD) [33] and
specific peptide chioromethyl ketones may more effectively
F - I -—
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established methodology we were unable to detect any PMN
granule contents within the supernatant of the incubations when
they were stimulated by GBMIgG*. However, when PMA was
used as the PMN stimulus, MPO was clearly detectable in the
supernatant (data not shown). Our studies suggest that using an
intact cell system the degradation is likely to be focused to the
point of PMN-GBM interaction. Thus, under these circum-
stances the local concentration of HNE may be very high and
saturate the capacity of any inhibitors present. In addition HNE
is highly cationic and binds to GBM [34] where it remains both
active and inaccessible to inhibition by alPi [28].
The production of ROS by neutrophils is dependent upon the
initial formation of superoxide by the membrane bound
NADPH-oxidase system [35], after which hydrogen peroxide
(H2O2) [30] and myeloperoxidase catalyzed hypochiorous acid
(HOC1) [36] formation may occur. Attempts to clarify the role
of ROS in the pathogenesis of tissue damage have yielded
conflicting data. Superoxide [6], H202 [2], HOC1 [35] and the
hydroxyl radical (OH-) [37] have all been implicated in animal
models of nephritis. In vitro studies of human PMN-mediated
matrix destruction have shown that H2O2 and HOC1 may both
be important [15, 16]. However, the use of the soluble neutro-
phil stimulus PMA in these studies makes interpretation of the
data uncertain for several reasons. PMA induces a relatively
potent respiratory burst with little degranulation [38, 39] and all
PMN in the incubates, including those not in direct contact with
substrate, are stimulated. Since PMN in contact with non-
phagocytosable surfaces and cells in suspension differ markedly
in their response to soluble stimuli [40, 41], PMA is effectively
stimulating different populations of PMN within the same
incubation. Thus ROS released from neutrophils in suspension
in the presence of PMA may not adequately reflect the in vivo
situation. We used chemiluminescence which allows a non-
invasive dynamic study of overall PMN respiratory burst activ-
ity to be assessed [26]. GBMIgG* produced a long lived, low
intensity neutrophil respiratory burst. Total CL activity over
the 120 minute incubations using this stimulus produced only 5
to 8% of the activity induced by PMA, further highlighting
important differences between the two stimuli.
In the present model the compound DPI was used to inhibit
PMN respiratory burst activity. DPI binds to, and inhibits, the
flavoprotein moiety of the NADPH-oxidase system [24] and
renders the PMN incapable of generating superoxide and sub-
sequent ROS including hydrogen peroxide, hydroxyl radicals
and hypohalous acids. Despite this, DPI treated PMN can still
degranulate normally and remain viable. Functionally, DPI
treated neutrophils resemble those of patients with chronic
granulomatous disease in whom NADPH-oxidase flavoprotein
levels are reduced [24]. The use of DPI has distinct advantages
over the use of oxygen radical scavengers and metal ion
chelators which have been extensively used to try and dissect
out the pathways involved in tissue injury by neutrophils
[14-16, 20, 37, 39, 42—44]. These latter compounds can only
work after the initial production of superoxide; they are non-
specific in their actions and their efficiency is dependent upon
the interaction rate constant between scavenger and radical
[14]. Another study, utilizing GBM as the PMN stimulus
showed that superoxide was detected only at the site of
PMN-substrate contact [45]. Poor penetration of scavengers
into this area may further increase their inefficiency. Accord-
ingly, it has been suggested that results obtained with intact cell
models which have utilized these agents should be interpreted
with caution [14].
In the absence of a proteinase inhibitor DPI did not affect the
ability of neutrophils to digest GBM. This has two main
implications. First, there is no evidence that ROS directly
caused type IV collagen degradation, though we cannot exclude
structural changes which could occur in the absence of soluble
products. Second, others have demonstrated that neutrophil-
derived HOC1 can activate the latent PMN metalloproteinase
gelatinase [16, 30]. This was not a significant factor in our acute
model since the theoretical increase in GBM degradation ex-
pected with normal PMN, as compared to DPI treated cells,
was not seen. It is also noteworthy that studies supporting this
ROS metalloproteinase activation have used PMA as the neu-
trophil stimulus [16, 30] which, as mentioned above, may
relatively exaggerate the effects of ROS. While this study has
failed to demonstrate a significant directly injurious role for
ROS against GBM, it does not exclude other potentially dam-
aging effects of these agents in GN. The present model is cell
free and therefore does not address the evidence that ROS can
injure resident glomerular cells, which could aggravate glomer-
ulonephritis [28, 29, 36, 37].
When the proteinase inhibitors were included in combination
with DPI some alteration of local elastase/anti elastase balance
was seen. Oxidation of the methionine residue 358, located in
the elastase binding site, reduces the inhibitory capacity of alPi
over 1000-fold [28]. Carp and Janoff proposed that this could
significantly alter proteinase/anti-proteinase balance to favor
proteolysis [14]. In the presence of low concentrations of alPi,
ROS from GBM-IgG stimulated neutrophils reduced its elastase
inhibitory capacity by up to —23%. The loss of this effect at
higher concentrations of alPi shows that only small amounts of
alPi were oxidized. Weiss and Regiani demonstrated that PMA
stimulated neutrophils could reduce alPi efficacy via an H2O2
dependent mechanism by up to 80% [15], an effect reduced by
higher concentrations of alPi. Conversely, Shah, Baricos and
Basci showed no such effect using the same stimulus and,
furthermore, could not prevent substrate degradation even in
the presence of excess alPi [16]. Moreover, Campbell et al
have emphasized that the cell-substrate contact during neutro-
phil activation may be important in limiting the oxidative
inactivation of alPi in vivo [17]. Our study shows that using an
homologous intact cell system oxidative inhibition of alPi is
small but significant.
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